A novel oxidized low-density lipoprotein marker, serum amyloid A-LDL, is associated with obesity and the metabolic syndrome.
BACKGROUND
The putative association between the novel oxidized low-density lipoprotein markers, serum amyloid A-LDL (SAA-LDL) and alpha1-antitrypsin-LDL (AT-LDL), and obesity and the metabolic syndrome (MetS) has not been previously studied. In the present report, we investigated the levels of SAA-LDL and AT-LDL in relation to the components of the MetS. We also assessed the effect of weight reduction therapy on serum SAA-LDL and AT-LDL levels among obese subjects.


METHODS
The study population included 421 obese Japanese outpatients (185 men and 236 women, mean age: 51.1 years) enrolled in the multicenter Japan Obesity and Metabolic Syndrome Study (JOMS). The novel oxidized low-density lipoprotein markers, serum SAA-LDL and AT-LDL, were measured in all participants.


RESULTS
Circulating SAA-LDL levels were independently associated with the presence and the number of components of the MetS. SAA-LDL levels were also significantly and independently correlated with high-sensitivity C-reactive protein. Notably, successful weight reduction resulted in a significant decrease in circulating SAA-LDL concentrations. Levels of AT-LDL were not associated with the MetS.


CONCLUSIONS
We documented, for the first time, that serum SAA-LDL levels correlate positively with the number of components of the MetS and weight reduction. Whether SAA-LDL may be involved in the pathophysiology of MetS and atherosclerosis deserves further investigation.
Kotani
Kazuhiko
K
Division of Preventive Medicine, Clinical Research Institute for Endocrine Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan. kazukotani@jichi.ac.jp
Satoh
Noriko
N
Kato
Yasuhisa
Y
Araki
Rika
R
Koyama
Kazunori
K
Okajima
Taiichiro
T
Tanabe
Makito
M
Oishi
Mariko
M
Yamakage
Hajime
H
Yamada
Kazunori
K
Hattori
Masakazu
M
Shimatsu
Akira
A
D000328:Adult; D000368:Aged; D044466:Asian People; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism; D004038:Diet, Reducing; D002149:Energy Intake; D015444:Exercise; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood* / Q000208:ethnology; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000208:ethnology / Q000628:therapy; D010045:Outpatients; D040242:Risk Reduction Behavior; D000685:Serum Amyloid A Protein / Q000032:analysis*; D016896:Treatment Outcome; D015431:Weight Loss; D000515:alpha 1-Antitrypsin / Q000097:blood
D015415:Biomarkers; D008077:Lipoproteins, LDL; C043392:SERPINA1 protein, human; D000685:Serum Amyloid A Protein; D000515:alpha 1-Antitrypsin; C099252:oxidized low density lipoprotein; D002097:C-Reactive Protein